RecruitingNCT07230067

Sepsis-associated Thrombocytopenia and Platelet Transfusion （STAPT）

The Impact of Platelet Transfusion Therapy on 28-day Mortality in Septic Patients With Thrombocytopenia During ICU Stay: a Multicenter Retrospective Observational Study

Sponsor

Nanfang Hospital, Southern Medical University

Enrollment

1,500 participants

Start Date

Nov 15, 2025

Study Type

OBSERVATIONAL

Conditions

Sepsis Sepsis and Coagulopathy

Summary

Currently, there are no multicenter studies on platelet transfusion for SAT patients, and the benefits and risks of platelet transfusion still require further validation based on large-sample data. In summary, investigating the correlation between platelet transfusion during ICU stay and 28-day mortality in SAT patients, as well as evaluating the impact of platelet transfusion on bleeding, thrombotic events, and inflammation control, is of great significance for optimizing SAT management strategies. This study aims to analyze the effect of platelet transfusion on the prognosis of SAT patients, thereby providing an evidence-based foundation for clinical decision-making.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Patients admitted to the ICU between January 2021 and May 2024 and subsequently discharged
Age ≥ 18 years
Meeting the Sepsis-3.0 diagnostic criteria
Platelet count < 100 × 10⁹/L at ICU admission
ICU length of stay ≥ 48 hours

Exclusion Criteria8

Active bleeding (e.g., major gastrointestinal bleeding, intracranial hemorrhage) or hematologic malignancies (e.g., leukemia, myelodysplastic syndrome, lymphoma);
Liver cirrhosis (Child-Pugh class B/C), chronic kidney disease (CKD stage 4-5), or autoimmune diseases (e.g., systemic lupus erythematosus);
Receipt of chemotherapy, immunosuppressants (e.g., cyclosporine, rituximab), or hematopoietic stem cell/solid organ transplantation within 2 weeks;
Pregnancy or lactation;
Pre-existing chronic thrombocytopenia (baseline platelet count <100×10⁹/L for >1 month) or long-term use of antiplatelet/anticoagulant drugs (>2 weeks);
Significant baseline coagulation dysfunction at ICU admission:Prothrombin time (PT) >1.5 times the upper limit of normal; Activated partial thromboplastin time (APTT) >1.5 times the upper limit of normal; Fibrinogen level <1.0 g/L;
APACHE II score ≥30 within 24 hours of ICU admission;
Missing >20% of key data (e.g., daily platelet counts, ICU survival status within 28 days).